Dendritic cell-based immunotherapy in ovarian cancer

PMID: 24501688
Journal: Oncoimmunology (volume: 2, issue: 12, Oncoimmunology 2013 Dec;2(12):e27059)
Published: 2013-11-06

Coosemans A, Vergote I, Van Gool SW


Worldwide, 80% of patients with ovarian cancer die of the disease. New treatments for this aggressive disease are therefore being intensively searched. Although dendritic cell-based vaccines against gynecological malignancies are in their infancy, this immunotherapeutic approach holds much promise. Here, we present our view on an optimal dendritic cell-based immunotherapeutic strategy against ovarian cancer.